Systemic mycoses: a potential alert for complications in COVID-19 patients

Future Microbiol. 2020 Sep:15:1405-1413. doi: 10.2217/fmb-2020-0156.

Abstract

As the global COVID-19 pandemic spreads worldwide, new challenges arise in the clinical landscape. The need for reliable diagnostic methods, treatments and vaccines for COVID-19 is the major worldwide urgency. While these goals are especially important, the growing risk of co-infections is a major threat not only to the health systems but also to patients' lives. Although there is still not enough published statistical data, co-infections in COVID-19 patients found that a significant number of patients hospitalized with COVID-19 developed secondary systemic mycoses that led to serious complications and even death. This review will discuss some of these important findings with the major aim to warn the population about the high risk of concomitant systemic mycoses in individuals weakened by COVID-19.

Keywords: COVID-19; aspergillosis; candidiasis; opportunistic fungi; pulmonary diseases; systemic mycosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / pathology
  • Glucocorticoids / adverse effects
  • Humans
  • Invasive Fungal Infections / complications
  • Invasive Fungal Infections / diagnosis
  • Invasive Fungal Infections / epidemiology
  • Invasive Fungal Infections / microbiology
  • Lung Diseases, Fungal / complications
  • Lung Diseases, Fungal / diagnosis
  • Lung Diseases, Fungal / epidemiology
  • Lung Diseases, Fungal / microbiology
  • Mycoses / complications*
  • Mycoses / diagnosis
  • Mycoses / epidemiology
  • Mycoses / microbiology
  • Opportunistic Infections / complications*
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / epidemiology
  • Opportunistic Infections / microbiology
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / pathology
  • Risk
  • SARS-CoV-2

Substances

  • Glucocorticoids